Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.0K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

723
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
723
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

777
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
777
Restless Leg Syndrome and Night Terrors01:27

Restless Leg Syndrome and Night Terrors

742
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
742
Neural Regulation01:37

Neural Regulation

44.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.1K
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

1.1K
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recombinant Phototagging Enables Fluorescent Labeling of Biomolecules.

Biomacromolecules·2026
Same author

Seroprevalence of Common Viruses in Early Infancy in North Indian Children with Biliary Atresia.

Journal of Indian Association of Pediatric Surgeons·2026
Same author

Plant Protease Inhibitors Induced Oxidative and Nutritional Stress in <i>Helicoverpa armigera</i> Unveils Multifaceted Survival Strategies: A Lipidomic and Metabolomic View.

ACS omega·2026
Same author

Early identification for palliative care integration and symptom burden within family medicine practice in South India.

BMJ supportive & palliative care·2026
Same author

Efficacy of <i>Bacopa monnieri</i> (Linn.) on Cognitive Function and Alterations in Blood Metabolites in Patients With Amnestic Mild Cognitive Impairment and Early Alzheimer Disease: Protocol for an Exploratory Double-Blind, Randomized, Placebo-Controlled Trial.

JMIR research protocols·2026
Same author

Downmodulation of cholesterol biosynthetic network governs activation of the innate immune response to Japanese encephalitis virus infection.

Journal of virology·2026

Related Experiment Video

Updated: Mar 17, 2026

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.7K

Neuroleptic malignant syndrome.

Bino Rajamani1, Yashwant Kumar2, Sajitha M F Rahman2

  • 1Low-Cost Effective Care Unit, CMC, Vellore, Tamil Nadu, India.

Journal of Family Medicine and Primary Care
|July 26, 2016
PubMed
Summary
This summary is machine-generated.

Neuroleptic malignant syndrome (NMS), a severe reaction to antipsychotic medications, presents with distinct symptoms. Early recognition and treatment are crucial for patient recovery from this life-threatening condition.

Keywords:
Antipsychotic agentsfamily physicianneuroleptic malignant syndrome

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.8K
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K

Related Experiment Videos

Last Updated: Mar 17, 2026

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.7K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.8K
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Medicine

Background:

  • Neuroleptic malignant syndrome (NMS) is a critical medical emergency associated with antipsychotic drug use.
  • NMS is defined by a characteristic tetrad of motor, behavioral, autonomic, and laboratory findings.
  • Antipsychotic agents are frequently implicated in the development of NMS.

Observation:

  • A case study involving a 34-year-old male with newly diagnosed Type 2 diabetes mellitus, intellectual disability, and behavioral issues.
  • The patient developed NMS following the initiation of antipsychotic therapy.
  • Clinical presentation included hyperthermia, muscle rigidity, tachycardia, and hypertension.

Findings:

  • The patient experienced a severe adverse reaction to antipsychotic medication, consistent with NMS.
  • The observed symptoms included fever, muscle stiffness, rapid heart rate, and elevated blood pressure.
  • Laboratory abnormalities, though not detailed, are a key diagnostic component of NMS.

Implications:

  • This case highlights the importance of vigilance for NMS in patients starting antipsychotic treatment, especially those with comorbidities.
  • Prompt medical intervention and management are essential for stabilizing patients with NMS.
  • Successful treatment and discharge indicate the potential for recovery from NMS with appropriate care.